57P SENDER™ directed LNP delivery of mRNA for in situ generation of highly potent CAR T cells

Résumé fourni par la source

CAR T cell therapies have shown success in cancer treatment, especially in hematologic malignancies. However, scalability, manufacturing, and inpatient treatment limit their broad use. A non-viral, off-the-shelf solution is key to overcoming these barriers, especially for indications outside oncology. Building on mRNA LNPs for in-vivo CAR T delivery, we developed SENDER (Specific Engager Nanoparticle DelivERy), a novel approach to redirect LNPs for targeted mRNA delivery to immune cells. SENDER proteins non-covalently bind to LNPs, redirect them to T cells, and block protein corona formation, reducing off-target accumulation in the liver.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.